PRECLINICAL/CLINICAL AIDS VACCINE DEVELOPMENT - ADDENDUM

Release Date:  April 3, 1998

PA NUMBER:  PAR-97-056

P.T.

National Institute of Allergy and Infectious Diseases

Application Receipt Dates:  July 30, 1998, July 30, 1999

PURPOSE

This notice is an addendum to Program Announcement (PA) PAR-97-056, Integrated
Preclinical/Clinical AIDS Vaccine Development, which was published in the NIH
Guide for Grants and Contracts, Vol. 26, No. 13, April 25, 1997
and the addendum published in the NIH Guide for Grants and Contracts,
Vol. 26, No. 18, May 30, 1997. 
The purpose of this notice is to inform potential applicants of significant
changes regarding the Research Objectives and Scope of the Program.  These
changes are effective for the future receipt dates beginning with July 30, 1998.

First, in order to emphasize the targeting of late-phase AIDS vaccine product
development intended by this program announcement, beginning with the July 30,
1998 receipt date, applications submitted under this PA may contain late stage
pre-clinical studies but they must include human testing as part of the proposed
work.  The plans for human testing must be feasible, realistic, and achievable
within the period of the award.

Second, NIH policy requires P01 applications to consist of at least three
projects and one core.  For this PA, fundable applications must have at least two
projects and one core.  Applicants for P01 grants must follow special application
guidelines in the NIAID Brochure entitled INSTRUCTIONS FOR APPLICATIONS FOR
MULTI-PROJECT AWARDS (September 1997); this brochure is available via the WWW at:
http://www.niaid.nih.gov/ncn/grants/multibron.htm

Third, in accordance with NIH policy, foreign institutions may not be awarded
grants for program projects.  For this initiative NIAID has made an exception. 
Foreign institutions may apply for grants under this initiative, however, all
other usual restrictions on foreign grant applications will apply.

Fourth, applicants requesting budgets greater than $500,000 in direct costs are
required to contact program staff in the appropriate NIH institute prior to
submitting their applications (NIH GUIDE, March 20, 1997).  Applicants with
budget of more than $500,000 in direct costs that are submitted without prior
communication with NIH program staff will not be accepted for review.

INQUIRIES

Inquiries concerning this program announcement are encouraged.  The opportunity
to clarify any issue or questions from potential applicants is welcome.

For questions concerning programmatic (scope and eligibility) issues, contact:

Dr. Steven Bende
Division of AIDS
National Institute of Allergy and Infectious Diseases
6003 Executive Boulevard, Room 2A29
Bethesda, MD  20892-7620
Rockville, MD  20852 (for express/courier service)
Telephone:  (301) 435-3756
FAX:  (301) 402-3684
Email:  [email protected]

Direct inquiries regarding review issues to:

Dr. Dianne Tingley
Division of Extramural Activities
National Institute of Allergy and Infectious Diseases
6003 Executive Boulevard, Room 4C07
Bethesda, MD  20892-7610
Rockville, MD 20852 (for express/courier service)
Telephone:  (301) 496-2550
FAX:  (301) 402-2638
Email:  [email protected]

Direct inquiries regarding fiscal matters to:

Laura Eisenman
Division of Extramural Activities
National Institute of Allergy and Infectious Diseases
6003 Executive Boulevard, Room 4C26
Bethesda, MD  20892-7610
Rockville, MD  20852 (for express/courier service)
Telephone:  (301) 402-5541
FAX:  (301) 480-3780
Email:  [email protected]

Return to Volume Index

Return to NIH Guide Main Index

	Office of Extramural Research (OER)			National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892			Department of Health and Human Services (HHS)